Viridian Therapeutics Announces 2024 Annual Meeting of Stockholders on June 17
Ticker: VRDN · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 1590750
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Director Election, Executive Compensation, Equity Incentive Plan
TL;DR
<b>Viridian Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 17, 2024, to elect directors, ratify auditors, and vote on executive compensation and equity plans.</b>
AI Summary
Viridian Therapeutics, Inc.\DE (VRDN) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Annual Meeting scheduled for June 17, 2024, at 3:00 p.m. ET, conducted virtually. Key agenda items include election of two Class III directors, ratification of KPMG LLP as independent auditor, and advisory approval of executive compensation. Stockholders will vote on an amendment to the 2016 Equity Incentive Plan, increasing shares available by 2,000,000. Record date for stockholders entitled to vote is April 23, 2024. The company was formerly known as Miragen Therapeutics, Inc. and Signal Genetics, Inc.
Why It Matters
For investors and stakeholders tracking Viridian Therapeutics, Inc.\DE, this filing contains several important signals. The meeting will address the election of directors and the ratification of the independent auditor, which are standard governance procedures crucial for company oversight. A key vote concerns the amendment to the equity incentive plan, indicating potential future stock-based compensation and dilution, impacting shareholder value.
Risk Assessment
Risk Level: low — Viridian Therapeutics, Inc.\DE shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Stockholders should review the proxy materials carefully to understand the director nominees, executive compensation proposals, and the proposed equity plan amendment before voting.
Key Numbers
- 2024 — Annual Meeting Year (2024 Annual Meeting of Stockholders)
- June 17 — Annual Meeting Date (Monday, June 17, 2024)
- 3:00 p.m. Eastern Time — Annual Meeting Time (3:00 p.m. Eastern Time)
- April 23, 2024 — Record Date (April 23, 2024)
- 2,000,000 — Share Increase (increase by 2,000,000 of the shares available for issuance thereunder)
Key Players & Entities
- Viridian Therapeutics, Inc. (company) — Name of Registrant
- KPMG LLP (company) — Independent registered public accounting firm
- June 17, 2024 (date) — Date of Annual Meeting
- April 23, 2024 (date) — Record date for stockholders
- 2,000,000 (dollar_amount) — Increase in shares for equity plan
- Miragen Therapeutics, Inc. (company) — Former company name
- Signal Genetics, Inc. (company) — Former company name
FAQ
When did Viridian Therapeutics, Inc.\DE file this DEF 14A?
Viridian Therapeutics, Inc.\DE filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Viridian Therapeutics, Inc.\DE (VRDN).
Where can I read the original DEF 14A filing from Viridian Therapeutics, Inc.\DE?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Viridian Therapeutics, Inc.\DE.
What are the key takeaways from Viridian Therapeutics, Inc.\DE's DEF 14A?
Viridian Therapeutics, Inc.\DE filed this DEF 14A on April 26, 2024. Key takeaways: Annual Meeting scheduled for June 17, 2024, at 3:00 p.m. ET, conducted virtually.. Key agenda items include election of two Class III directors, ratification of KPMG LLP as independent auditor, and advisory approval of executive compensation.. Stockholders will vote on an amendment to the 2016 Equity Incentive Plan, increasing shares available by 2,000,000..
Is Viridian Therapeutics, Inc.\DE a risky investment based on this filing?
Based on this DEF 14A, Viridian Therapeutics, Inc.\DE presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading Viridian Therapeutics, Inc.\DE's DEF 14A?
Stockholders should review the proxy materials carefully to understand the director nominees, executive compensation proposals, and the proposed equity plan amendment before voting. The overall sentiment from this filing is neutral.
How does Viridian Therapeutics, Inc.\DE compare to its industry peers?
Viridian Therapeutics operates in the biotechnology sector, focusing on developing therapeutics. This filing is a standard proxy statement for a publicly traded company.
Are there regulatory concerns for Viridian Therapeutics, Inc.\DE?
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.
Industry Context
Viridian Therapeutics operates in the biotechnology sector, focusing on developing therapeutics. This filing is a standard proxy statement for a publicly traded company.
Regulatory Implications
The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.
What Investors Should Do
- Review the proxy statement for details on director nominees and their qualifications.
- Evaluate the proposed amendment to the 2016 Equity Incentive Plan, considering potential share dilution.
- Understand the advisory vote on executive compensation and its alignment with company performance.
Key Dates
- 2024-06-17: 2024 Annual Meeting of Stockholders — To elect directors, ratify auditors, approve executive compensation, and vote on equity plan amendments.
- 2024-04-23: Record Date — Determines which stockholders are entitled to vote at the Annual Meeting.
Year-Over-Year Comparison
This is a DEF 14A filing for the 2024 Annual Meeting, following previous filings related to the company's operations and governance.
Filing Stats: 4,752 words · 19 min read · ~16 pages · Grade level 12.8 · Accepted 2024-04-26 08:30:49
Key Financial Figures
- $50,000 — n soliciting proxies for a fee of up to $50,000, plus distribution costs and other expe
Filing Documents
- d797640ddef14a.htm (DEF 14A) — 656KB
- g797640dsp64.jpg (GRAPHIC) — 4KB
- g797640g00a10.jpg (GRAPHIC) — 122KB
- g797640g00a11.jpg (GRAPHIC) — 83KB
- g797640g53e52.jpg (GRAPHIC) — 28KB
- 0001193125-24-115928.txt ( ) — 981KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 33 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS 36
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 37 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 50 OTHER MATTERS 53 APPENDIX A VIRIDIAN THERAPEUTICS, INC. AMENDED & RESTATED 2016 EQUITY INCENTIVE PLAN A-1 LEGAL MATTERS Important Notice Regarding the Availability of Proxy Materials for the 2024 Annual Meeting of Stockholders to Be Held on June 17, 2024. The Proxy Statement and Annual Report for the year ended December 31, 2023 are available at www.proxyvote.com .
Forward-Looking Statements. The Proxy Statement may contain forward-looking statements within the meaning of the safe
Forward-Looking Statements. The Proxy Statement may contain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements other than statements of historical fact included in the Proxy Statement are forward-looking statements, including statements about the Companys Board of Directors, corporate governance practices, executive compensation program and equity compensation utilization. In some cases, you can identify forward-looking statements by terms such as may, might, will, objective, intend, should, could, can, would, expect, believe, design, estimate, predict, potential, plan or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in the Proxy Statement. Such risks, uncertainties and other factors include those risks described in Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations in the Companys most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and other subsequent documents we file with the SEC. The Company expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law. Website References. Website references throughout this document are inactive textual references and provided for convenience only, and the content on the referenced websites is not incorporated herein by reference and does not constitute a part of the Proxy Statement. Use of Trademarks. Viridian Therapeutics is the trademark of Viridian Therapeutics, Inc. Othe